--- title: "Intra-Cellular Therapies (NASDAQ:ITCI) Hits New 52-Week High - Here's Why" type: "News" locale: "en" url: "https://longbridge.com/en/news/230452320.md" description: "Intra-Cellular Therapies (NASDAQ:ITCI) reached a new 52-week high of $131.35 during trading, closing at $131.28. Analyst ratings have varied, with Canaccord Genuity downgrading the stock from \"buy\" to \"hold\" but raising the price target to $132. The company reported a quarterly loss of $0.16 per share, missing estimates, with revenue of $199.22 million. Insider trading saw CEO Sharon Mates sell 51,000 shares. Institutional investors hold 92.33% of the stock, reflecting strong interest in the biopharmaceutical firm focused on neuropsychiatric disorders." datetime: "2025-03-04T09:01:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/230452320.md) - [en](https://longbridge.com/en/news/230452320.md) - [zh-HK](https://longbridge.com/zh-HK/news/230452320.md) --- # Intra-Cellular Therapies (NASDAQ:ITCI) Hits New 52-Week High - Here's Why Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $131.35 and last traded at $131.28, with a volume of 7155386 shares changing hands. The stock had previously closed at $128.20. ## Analyst Ratings Changes - MarketBeat Week in Review – 01/13 - 01/17 ITCI has been the subject of a number of analyst reports. Canaccord Genuity Group downgraded Intra-Cellular Therapies from a "buy" rating to a "hold" rating and boosted their price objective for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. Mizuho downgraded shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and decreased their price target for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Needham & Company LLC reissued a "hold" rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Baird R W lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and set a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Ten investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Intra-Cellular Therapies presently has a consensus rating of "Hold" and a consensus target price of $106.08. **Read Our Latest Report on ITCI** ## Intra-Cellular Therapies Trading Up 2.4 % - Is Johnson & Johnson Stock Set to Reward Long-Term Holders? The firm has a market capitalization of $13.96 billion, a PE ratio of -150.89 and a beta of 0.72. The company has a fifty day moving average price of $115.52 and a two-hundred day moving average price of $92.12. Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, equities research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year. ## Insider Buying and Selling - Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.60% of the stock is owned by company insiders. ## Hedge Funds Weigh In On Intra-Cellular Therapies Hedge funds and other institutional investors have recently made changes to their positions in the stock. Accredited Wealth Management LLC acquired a new stake in Intra-Cellular Therapies during the 4th quarter worth approximately $28,000. True Wealth Design LLC purchased a new stake in shares of Intra-Cellular Therapies during the third quarter worth approximately $32,000. GAMMA Investing LLC lifted its holdings in shares of Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 240 shares during the period. Capital Performance Advisors LLP acquired a new stake in shares of Intra-Cellular Therapies during the third quarter worth $74,000. Finally, Venturi Wealth Management LLC purchased a new position in Intra-Cellular Therapies in the 4th quarter valued at $96,000. Hedge funds and other institutional investors own 92.33% of the company's stock. ## About Intra-Cellular Therapies (Get Free Report) Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. ## Featured Stories - Five stocks we like better than Intra-Cellular Therapies - How to find penny stocks to invest and trade - Bearish Investors Can Seek Refuge in Recession-Resistant ETFs - Using the MarketBeat Stock Split Calculator - 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now? - How Can Investors Benefit From After-Hours Trading - 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Intra-Cellular Therapies Right Now? Before you consider Intra-Cellular Therapies, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list. While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ITCI.US](https://longbridge.com/en/quote/ITCI.US.md) ## Related News & Research - [Insider Selling: CommVault Systems (NASDAQ:CVLT) CAO Sells 486 Shares](https://longbridge.com/en/news/296409914.md) - [Insider Selling: Universal Electronics (NASDAQ:UEIC) Major Shareholder Sells 8,300 Shares of Stock](https://longbridge.com/en/news/296418149.md) - [Zillow Group (NASDAQ:Z) Insider Dan Spaulding Sells 3,169 Shares](https://longbridge.com/en/news/296154121.md) - [Insider Selling: Gloo (NASDAQ:GLOO) Major Shareholder Sells 4,000 Shares of Stock](https://longbridge.com/en/news/296410780.md) - [Agilysys Insiders Sold Shares Worth Over $1.6M](https://longbridge.com/en/news/296401909.md)